SICOR REACQUIRES MARKETING RIGHTS TO AAIPHARMA'S CALCITRIOL

aaiPharma has announced that SICOR Pharmaceuticals, a wholly owned subsidiary of Teva Pharmaceutical Industries, has reacquired its U.S. marketing rights for calcitriol injection in exchange for certain payments to aaiPharma. Calcitriol injection vial is a drug used primarily to treat chronic kidney dialysis patients with abnormally low levels of calcium in their blood.

PharmaBiz.com (http://www.pharmabiz.com/article/detnews.asp?articleid=25424)